Abstract
In order to determine the potential role that various antifungal agents might have in the management of cryptococcosis in tropical areas, the in vitro susceptibility of Cryptococcus neoformans isolates from Africa (n=52) and Cambodia (n=110) to three antifungal agents (amphotericin B, fluconazole and voriconazole) were compared using the E-test method. The results of this study (i) confirm the value of the E-test for testing the in vitro susceptibility of C. neoformans towards voriconazole; (ii) provide the first evidence demonstrating good activity of amphotericin B, fluconazole and voriconazole against Cambodian isolates; and (iii) show there are differences in susceptibility between African and Asian C. neoformans isolates, with Cambodian isolates appearing less susceptible to the agents tested but with amphotericin B maintaining good activity.
Similar content being viewed by others
References
Mitchell TG, Perfect JR (1995) Cryptococcosis in the era of AIDS—100 years after the discovery of Cryptococcus neoformans. Clin Microbiol Rev 8:515–548
Pfaller MA, Zhang J, Messer SA, Brandt ME, Hajjeh RA, Jessup CJ, Tumberland M, Mbidde EK, Ghannoum MA (1999) In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa. Antimicrob Agents Chemother 43:169–171
Espinel-Ingroff A, Boyle K, Sheehan DJ (2001) In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature. Mycopathologia 150:101–115
Hoffman HL, Rathbun RC (2002) Review of the safety and efficacy of voriconazole. Expert Opin Investig Drugs 11:409–429
Douchet C, Chandenier J, Barrabes A, Therizol-Ferly M, Richard-Lenoble D (1995) Rapid recognition of Cryptococcus neoformans colony with an easy method. J Mycol Med 5:122–123
Rex JH, Pfaller MA (2002) Has antifungal susceptibility testing come of age? Clin Infect Dis 35:982–989
Hoffman HL, Pfaller MA (2001) In vitro antifungal susceptibility testing. Pharmacotherapy 21 (8 Pt 2):111S–123S
Lozano-Chiu M, Paetznick VL, Ghannoum MA, Rex JH (1998) Detection of resistance to amphotericin B among Cryptococcus neoformans clinical isolates: performances of three different media assessed by using E-test and National Committee for Clinical Laboratory Standards M27-A methodologies. J Clin Microbiol 36:2817–2822
Chryssanthou E, Gronfors C, Khanna N (1997) Comparison of broth macrodilution, broth microdilution and E-test susceptibility tests of Cryptococcus neoformans for fluconazole. Mycoses 40:423–427
Maxwell MJ, Messer SA, Hollis RJ, Diekema DJ, Pfaller MA (2003) Evaluation of E-test for determining voriconazole and amphotericin B MICs for 162 clinical isolates of Cryptococcus neoformans. J Clin Microbiol 41:97–99
Brandt ME, Pfaller MA, Hajjeh RA, Hamill RJ, Pappas PG, Reingold AL, Rimland D, Warnock DW (2001) Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates in the United States: 1992 to 1994 and 1996 to 1998. Antimicrob Agents Chemother 45:3065–3069
Davey KG, Johnson EM, Holmes AD, Szekely A, Warnock DW (1998) In vitro susceptibility of Cryptococcus neoformans isolates to fluconazole and itraconazole. J Antimicrob Chemother 42:217–220
Pichith K, Chanroeun H, Bunna P, Nyvanny N, Thavary S, Kosal,S, Crepin P (2001) Clinical aspects of AIDS at the Calmette hospital in Phnom Penh, Kingdom of Cambodia. A report on 356 patients hospitalized in the Medicine “B” Department of the Calmette Hospital. Sante 11:17–23
Poonwan N, Mikami Y, Poosuwan S, Boon-Long J, Mekha N, Kusum M, Yazawa K, Tanaka R, Nishimura K, Konyama K (1997) Serotyping of Cryptococcus neoformans strains isolated from clinical specimens in Thailand and their susceptibility to various antifungal agents. Eur J Epidemiol 13:335–340
Wuthiekanun V, Howe PA, Simpson AJ, Smith MD, Walsh AL, Angus BJ, Rajchanuwong A, White NJ (1999) Antifungal susceptibilities of Cryptococcus neoformans in north-east Thailand. Trans R Soc Trop Med Hyg 93:96–97
Acknowledgements
We thank Pfizer for kindly providing the voriconazole E-test strips and for help with the translation of this article. The 19 strains from Rwanda used in this study are available at “BCCM/IHEM biomedical fungi and yeasts collection, Scientific Institute of Public Health, Wytsan Street 14, 1050 Brussels, Belgium”.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chandenier, J., Adou-Bryn, K.D., Douchet, C. et al. In vitro activity of amphotericin B, fluconazole and voriconazole against 162 Cryptococcus neoformans isolates from Africa and Cambodia. Eur J Clin Microbiol Infect Dis 23, 506–508 (2004). https://doi.org/10.1007/s10096-004-1136-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10096-004-1136-2